莱美药业 (300006)
Chongqing Lummy Pharmaceutical Co.,Ltd.
K-Line Chart
No K-line data
Stock Details
1. Key Indicators
- Total Shares(W): 105591.12
- Circulating A-Shares(W): 105582.09
- Earnings Per Share(RMB): -0.0435
- Net Assets Per Share(RMB): 1.7413
- Operating Revenue(W RMB): 58106.28
- Total Profit(W RMB): -4758.75
- Net Profit Attributable to Parent(W RMB): -4591.72
- Net Profit Growth Rate(%): -73.82
- Weighted Return on Equity(%): -2.4800
- Operating Cash Flow Per Share(RMB): -0.0030
- Undistributed Profit Per Share(RMB): -0.5619
- Capital Reserve Per Share(RMB): 1.4059
2. Main Business
The main business covers:
- Pharmaceutical Manufacturing
3. Company Basic Information
- Company Name: Chongqing Lummy Pharmaceutical Co., Ltd.
- Listing Date: 2009-10-30
- Industry: Pharmaceutical Manufacturing
- Address: 15th and 16th Floor, Building B, Chongqing Academy of Science and Technology, No. 2 Yangliu Road, Huangshan Avenue, Yubei District, Chongqing
- Website: www.cqlummy.com
- Company Profile: The company was established as a joint-stock company through the overall change of Chongqing Lummy Pharmaceutical Co., Ltd. It was registered and approved by the Chongqing Administration for Market Regulation on October 16, 2007, with a registered capital of 68.5 million yuan.
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | Guangxi Wuzhou Zhongheng Group Co., Ltd. | Corporate Legal Person | 24742.61 | 23.43 |
| 2 | Tongde Qianyuan (Beijing) Investment Management Co., Ltd. - Nanning Zhongheng Tongde Pharmaceutical Industry Investment Fund Partnership (Limited Partnership) | Asset Management Plan | 2144.78 | 2.03 |
| 3 | Guangxi Guofu Innovation Equity Investment Fund Management Co., Ltd. - Guangxi Guangtou Guohong Health Industry Fund Partnership (Limited Partnership) | Asset Management Plan | 1111.11 | 1.05 |
5. Concept Sectors
- Immunotherapy
- Smart Healthcare
- Intellectual Property
- Helicobacter Pylori
- Assisted Reproduction
- Hepatitis Concept
- Innovative Drugs
- Margin Trading & Securities Lending
- Consecutive Losses
- Proposed Reduction
- Small-Cap State-Owned Enterprise
Remarks
- Data update date: 2026-01-01
- Data source: Public Market Information